Skip to main content
Journal ArticleOPEN ACCESS

Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

  • Demetri G
  • Paz-Ares L
  • Farago A
  • et al.
Annals of Oncology (2018) 29 viii713
DOI: 10.1093/annonc/mdy424.017
N/ACitations
Citations of this article
23Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Conclusions: In this multicenter, pooled analysis of global clinical trials, entrectinib was well tolerated overall and induced clinically meaningful, durable systemic responses in pts with NTRK-fp solid tumors, type agnostic, with and without CNS disease.Clinical trial identification: EudraCT: 2012-000148-88; NCT02097810; NCT02568267.Legal entity responsible for the study: F. Hoffmann-La Roche.

Cite

CITATION STYLE

APA

Demetri, G. D., Paz-Ares, L., Farago, A. F., Liu, S. V., Chawla, S. P., Tosi, D., … Doebele, R. C. (2018). Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Annals of Oncology, 29, viii713. https://doi.org/10.1093/annonc/mdy424.017

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free